Drugs / Farydak
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Farydak | — | 2015-08-28 | europa.eu ↗ |
| Approved | US (FDA) | FARYDAK | — | 2015-02-23 | fda.gov ↗ |
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02720510 Comparator | Jun 2016 → May 2017 | plasma cell myeloma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Farydak | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02720510 ↗ |